Pricing

Rallybio Corp (RLYB)

followers ยท
Sector: HEALTH CARE
Industry: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
CEO: Martin W. MacKay
Employees: 40
Web site: rallybio.com
234 CHURCH STREET, SUITE 1020, NEW HAVEN, CT, 06510
203- 859-3820
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Rallybio Corporation engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT)
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available